Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Healthcare Medical Devices
Theralase Technologies Inc. is a Canada-based clinical stage pharmaceutical company. The Company is engaged in the research and development of light, radiation, sound and/or drug-activated small molecule compounds, their associated drug formulations and the light systems that activate them, with a primary objective of efficacy and a secondary objective of safety in the destruction of various cancers, bacteria and viruses. It operates through two divisions: the Drug Division and the Device Division. The Drug Division is responsible for the research and development of light-activated small molecules primarily for the treatment of cancer with assistance from the Device Division to develop medical lasers to activate them. The Device Division is responsible for the Company’s medical laser business, which research, develops, manufactures and distributes cool laser therapy (CLT) systems to healthcare practitioners, predominantly for the healing of pain.


TSXV:TLT - Post by User

Theralase Technologies Inc.
Bullboard Posts
User Avatar Image
(510)
•••
Comment by 2b7f6fabon Jul 17, 2020 3:40pm
189 Views
Post# 31282999

RE:RE:Positive data..ph2

RE:RE:Positive data..ph2According to this article near the bottom indicates that Merck's keytruda patents expire in 2028 for both US and EU.   Just eight short years away.  JMO but who so ever acquires tld1433 and related patents will own the cancer space for a long time to come.  A couple years ago someone posted there were two large pharma watching tlt.  I suspect by now they are all watching.  Don't sell your shares to the first bidder.

https://www.forbes.com/sites/greatspeculations/2019/08/29/how-important-is-keytruda-for-merck/#43d05b1d1b4d




Quattro74 wrote:
if it is like phase 1 'optimal procedure' final two then the %s will be high. Should send shareprice up big. I've always thought TLT a buyout play. They better do it soon tho if they expect to get us for ~ $2B US. If they wait until after phase 1 data from Roswell Park or TLT gets close to Accelerated Approval(commercial start) Then it will be way too late for a cheapo deal.

VentureGuy24 wrote: What is our stock worth???

Lets hear it!

Buyout play or TLT turns into big pharma 




Bullboard Posts
Dealroom for high-potential pre-IPO opportunities